Rockwell Med (RMTI) AI Stock Analysis

• Market Cap: $36.84M
• Dividend Yield: N/A
• Average Volume (3M): 520.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.78
• Revenue Growth: -23.60%
• EPS Growth: -179.33%
• Country: US
• Employees: 244
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.05
• Shares Outstanding: 34,430,350
• 10 Day Avg. Volume: 418,188
• 30 Day Avg. Volume: 520,771
• PEG Ratio: 1.42
• Price to Book (P/B): 1.94
• Price to Sales (P/S): 0.62
• P/FCF Ratio: 19.86
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $3.75
• Price Target Upside: 312.09% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $1.00 ▲(9.89% Upside)

Rockwell Med's overall stock score is primarily impacted by its financial struggles, including declining revenues and profitability issues. Technical analysis indicates bearish momentum, and valuation metrics reflect ongoing losses. While the earnings call provided some positive developments, significant challenges remain, particularly with declining sales and customer transitions.

Positive Factors

Contract Portfolio Strengthening

Long-term agreements with customers provide stability and revenue visibility, enhancing Rockwell Medical's market position and reducing revenue volatility.

Improved Cash Position

An improved cash position provides Rockwell Medical with the flexibility to invest in growth opportunities and manage operational needs, supporting long-term financial health.

Operational Efficiency

Efforts to enhance operational efficiency can lead to cost savings and improved margins, supporting sustainable profitability and competitive advantage in the long term.

Negative Factors

Declining Revenue

A significant decline in revenue indicates challenges in maintaining market share and customer base, which could impact long-term growth and profitability.

Customer Transition Challenges

Delays and issues in customer transitions can disrupt revenue streams and strain relationships, affecting Rockwell Medical's ability to stabilize its market position.

Negative Cash Flow

Persistent negative cash flow highlights inefficiencies in cash management, which can limit Rockwell Medical's ability to invest in growth and meet financial obligations.

Rockwell Med Business Overview & Revenue Model

Company Description

Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

How the Company Makes Money

Rockwell Medical generates revenue primarily through the sale of its proprietary product Triferic, which is marketed to dialysis clinics and healthcare providers. The company earns income from both direct sales and potential partnerships with larger pharmaceutical companies that can help in distribution and market reach. Additionally, RMTI may benefit from collaborations in research and development, which can lead to new product offerings or enhancements to existing therapies. The company's revenue model is also supported by ongoing efforts to expand its market presence and increase adoption rates among healthcare providers, thereby driving sales growth.

Rockwell Med Financial Statement Overview

Summary

Rockwell Med faces financial challenges with declining revenues and persistent profitability issues. Despite some improvements in cost management, the company struggles with negative cash flows and profitability, indicating a need for stronger financial strategies.

Income Statement

Rockwell Med's income statement shows a declining revenue trend with a negative revenue growth rate of -14.08% in the TTM period. The company has struggled with profitability, as indicated by negative net profit and EBIT margins. However, the gross profit margin has slightly improved over time, suggesting some cost management improvements.

Balance Sheet

The balance sheet reflects moderate leverage with a debt-to-equity ratio of 0.46 in the TTM period, which is an improvement from previous years. However, the return on equity remains negative, indicating ongoing challenges in generating returns for shareholders. The equity ratio is not explicitly provided, but the overall financial health suggests a need for stronger equity growth.

Cash Flow

Cash flow analysis reveals significant challenges, with negative operating and free cash flows in the TTM period. The free cash flow growth rate is also negative, highlighting cash management issues. The operating cash flow to net income ratio is low, indicating inefficiencies in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	75.58M	101.49M	83.61M	72.81M	61.93M	62.20M
Gross Profit	11.45M	17.48M	8.70M	4.08M	-2.42M	2.73M
EBITDA	-2.68M	2.95M	-4.69M	-16.17M	-27.80M	-26.72M
Net Income	-5.52M	-480.00K	-8.44M	-18.68M	-32.67M	-30.89M
Balance Sheet
Total Assets	57.49M	59.21M	52.17M	46.63M	48.57M	77.75M
Cash, Cash Equivalents and Short-Term Investments	23.71M	21.60M	10.94M	21.49M	22.44M	58.68M
Total Debt	13.13M	13.54M	13.44M	16.36M	28.89M	23.94M
Total Liabilities	20.47M	26.62M	30.88M	32.53M	46.04M	43.58M
Stockholders Equity	37.02M	32.59M	21.29M	14.11M	2.54M	34.17M
Cash Flow
Free Cash Flow	-2.94M	3.19M	-9.70M	-17.21M	-34.06M	-30.69M
Operating Cash Flow	-2.08M	4.20M	-9.41M	-16.93M	-33.53M	-29.64M
Investing Cash Flow	-4.75M	-4.87M	-3.04M	-2.40M	311.00K	3.21M
Financing Cash Flow	8.10M	7.35M	11.34M	16.15M	-2.18M	63.32M

Rockwell Med Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.91
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RMTI, the sentiment is Negative. The current price of 0.91 is below the 20-day moving average (MA) of 0.98, below the 50-day MA of 1.12, and below the 200-day MA of 1.19, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 37.30 is Neutral, neither overbought nor oversold. The STOCH value of 34.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RMTI.

Rockwell Med Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ASRT	49 Neutral	$69.79M	-1.60	-24.48%	―	9.21%	58.12%
CPIX	49 Neutral	$39.79M	-12.47	-13.08%	―	12.21%	69.91%
SCYX	46 Neutral	$26.45M	-1.11	-53.29%	―	-65.77%	38.61%
RMTI	41 Neutral	$36.84M	―	-16.67%	―	-23.60%	-179.33%
KALA	31 Underperform	$5.28M	-0.11	―	―	―	52.39%

Rockwell Med Corporate Events

Rockwell Medical Reports Q3 2025 Earnings and Strategic Moves

Rockwell Medical, Inc. is a healthcare company that develops, manufactures, and distributes hemodialysis products for dialysis providers worldwide, focusing on enhancing product quality and customer service. In its third-quarter 2025 earnings report, Rockwell Medical reported net sales of $15.9 million and achieved profitability on an Adjusted EBITDA basis, while increasing its cash position to $23.7 million. However, the company experienced a significant decline in net sales and gross profit compared to the previous year, primarily due to the loss of its largest customer to a competitor. Despite these challenges, Rockwell Medical signed new long-term agreements with various medical centers and expanded its product purchase agreement with a major dialysis provider, indicating strategic efforts to stabilize and grow its customer base. Looking ahead, Rockwell Medical remains focused on expanding its product portfolio and geographic presence, while maintaining strict expense discipline to achieve sustainable profitability.

Rockwell Medical’s Earnings Call: A Mixed Transition

Rockwell Medical’s recent earnings call paints a picture of a company navigating through a transitional phase with mixed results. While the company achieved profitability on an adjusted EBITDA basis and successfully bolstered its contract portfolio, it also faced significant challenges, including a decline in net sales and gross profit, alongside ongoing customer transition issues. The improved cash position and expansion of the customer base are promising, yet substantial hurdles remain.

Rockwell Med Releases Updated Corporate Presentation

On November 12, 2025, Rockwell Medical, Inc. released an updated corporate presentation. This update is part of their ongoing efforts to provide stakeholders with current information, though it is not considered filed under the Securities Exchange Act of 1934.

The most recent analyst rating on (RMTI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Rockwell Med stock, see the RMTI Stock Forecast page.

Rockwell Med Appoints Heather Hunter as COO

On September 23, 2025, Rockwell Medical appointed Heather Hunter as the Senior Vice President and Chief Operating Officer. Ms. Hunter’s extensive experience in corporate affairs and communications, notably with Venatorx Pharmaceuticals and Safeguard Scientifics, positions her to significantly impact Rockwell Medical’s strategic operations and industry standing. Her employment agreement includes provisions for salary, bonuses, and stock options, reflecting the company’s commitment to aligning executive incentives with long-term growth objectives.

The most recent analyst rating on (RMTI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Rockwell Med stock, see the RMTI Stock Forecast page.

Rockwell Medical Navigates Transition Amid Financial Challenges

Rockwell Medical’s recent earnings call paints a picture of a company in transition, grappling with both setbacks and strategic advancements. While the financial performance has been impacted by the loss of a major customer, the company has made strides in improving its cash reserves, securing long-term contracts, and maintaining operational efficiency. These positive developments indicate a potential for future growth, although the current financial challenges remain a concern.

Rockwell Medical Reports Q2 2025 Financial Results

Rockwell Medical, Inc. is a healthcare company specializing in the development, manufacture, and distribution of hemodialysis products for dialysis providers worldwide. The company is known for its commitment to high-quality products and excellent customer service.